HISUN

HISUN is a comprehensive pharmaceutical enterprise that integrates the entire value chain of research, production, and marketing, with a combination of active pharmaceutical ingredients and formulations, and multi-regional development. Founded in 1956 and listed on the A-share market in 2000, it is a state-controlled listed company. HISUN is one of the largest production bases for antibiotics and anti-tumor drugs in China, and has been repeatedly included in the lists of the top 500 manufacturing enterprises in China and the top 100 pharmaceutical industrial enterprises in China. In 2020, it was praised by the Joint Prevention and Control Group of the State Council as an "armament factory" in the fight against the epidemic, and was awarded the title of "Advanced Collective in the Fight Against COVID-19 in the Industrial and Information System." Starting from a chemical enterprise, HISUN entered the pharmaceutical field in the early 1970s and has always adhered to the main business for more than 60 years. It now has total assets of 20 billion yuan and sales exceeding 10 billion yuan. The company focuses on the research, production, and sales of innovative drugs, biologics, generic drugs, and high-end active pharmaceutical ingredients, covering more than ten therapeutic areas such as anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressants, and orthopedics. As one of the first batch of innovative enterprises in China, HISUN has established a Central Research Institute at its Taizhou headquarters, with a national-level technical center, a postdoctoral research workstation with independent recruitment qualifications, and a provincial academician workstation. The company adheres to the dual-wheel drive of independent research and cooperative research, accelerating the application and transformation of new products. In recent years, it has undertaken 47 national major new drug creation projects, won two National Technology Invention Awards (second prize), nine provincial and ministerial science and technology progress awards, applied for more than 1,000 patents, owned more than 300 authorized patents, and received five China Patent Excellence Awards and one Zhejiang Province Patent Excellence Award. In recent years, the company has actively expanded its upstream and downstream integrated business from active pharmaceutical ingredients to formulations around the strategic goal of "focus, slimming, and optimization," while taking the lead in laying out the large health industry and accelerating the development of the domestic special medical food market. Its anti-infection drugs and anti-tumor drugs rank among the top in the Chinese market, with 20 varieties having individual sales exceeding 100 million yuan. Eighty percent of the company's active pharmaceutical ingredient revenue comes from overseas markets, with exports covering more than 70 countries and regions worldwide. The domestic formulation sales network covers all over China, with nearly 10,000 hospitals using its drugs. HISUN is committed to "persevering in drug innovation and achieving the dream of healthy longevity," delivering world-class quality, showcasing a new image of HISUN, focusing on building a new brand, promoting HISUN to become a sustainably healthy comprehensive pharmaceutical enterprise, and contributing to the cause of human life and health.